{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:05:51Z","timestamp":1751947551443,"version":"3.41.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Little is reported in literature about Parkinson\u2019s disease and treatment responses among South Asians. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>Under the supervision of a movement disorders neurologist, an 85-year-old South Asian American man in hospice care was sufficiently regenerated from an adjustment of medications for Parkinson\u2019s disease, such that he was able to shift from being immobile, unable to speak, or safely eat and drink fluids orally, to walking, eating, drinking fluids, and communicating again. His initial symptoms motivated him to seek neurological care in 2012, with his first consultation with a movement disorders neurologist occurring in 2023. After receiving specialty care and adjusting his carbidopa\u2013levodopa from immediate release to a combination short- and long-acting formulation, Rytary, he was discharged from hospice to home health care. He progressed from being almost entirely nonverbal, bed-bound, and solely dependent on artificial nutrition to supportive home-based physical therapy, which facilitated his ability to regain sufficient strength for ambulation, eating and drinking orally, and he can once again use expressive language.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Immediate-release carbidopa\u2013levodopa given three to four times daily remains the most common medication regimen for managing Parkinson\u2019s disease symptoms of tremor and rigidity, with benefits noted in responsive patients for 2 to 3\u00a0hours. Extended release and combination formulations of carbidopa\u2013levodopa that combine short- and long-acting medications in one capsule provide symptom relief for responsive patients for 4\u20136\u00a0hours and should be considered when the benefit from immediate-release carbidopa\u2013levodopa is limited. Little has previously been published about the potential for variations in carbidopa\u2013levodopa formulation responsiveness in South Asians, though it has been suggested that Western guidelines for managing \u201coff\u201d periods where carbidopa\u2013levodopa is less effective, may not apply to other ethnicities (Bhidayasiri <jats:italic>et al<\/jats:italic>. in Expert Rev Neurother 15(11):1285\u20131297, 2015). As exemplified in this case, greater understanding of non-Caucasian races\u2019 responses to carbidopa\u2013levodopa, extended release, and their combination formulas is needed as is the benefit from subspecialty care within neurology, where the art of medication management is enhanced by experience in movement disorders and where objective tools such as the Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale can measure stability, decline, or improvement within each patient pertaining to their activities of daily living, cognitive and motor functions impacted by Parkinson\u2019s disease, as well as monitoring for adverse reactions to medications used for Parkinson\u2019s disease, such as dyskinesias.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13256-025-05385-x","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T09:04:02Z","timestamp":1751879042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptom improvement in a South Asian patient with Parkinson\u2019s disease treated with immediate- and extended-release carbidopa\u2013levodopa: a case report"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-7332","authenticated-orcid":false,"given":"Gail","family":"Reiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Skipworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"5385_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/NDT.S273121","volume":"19","author":"N Masood","year":"2023","unstructured":"Masood N, Jimenez-Shahed J. Effective management of \u201cOFF\u201d episodes in Parkinson\u2019s disease: emerging treatment strategies and unmet clinical needs. Neuropsychiatr Dis Treat. 2023;19:247\u201366.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"5385_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548\u201360.","journal-title":"JAMA"},{"key":"5385_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13550-015-0087-1","volume":"5","author":"SR Suwijn","year":"2015","unstructured":"Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson\u2019s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res. 2015;5:12.","journal-title":"EJNMMI Res"},{"issue":"1","key":"5385_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/JPD-191763","volume":"10","author":"A Ben-Joseph","year":"2020","unstructured":"Ben-Joseph A, Marshall CR, Lees AJ, Noyce AJ. Ethnic variation in the manifestation of Parkinson\u2019s disease: a narrative review. J Parkinsons Dis. 2020;10(1):31\u201345.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"5385_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000275491","volume":"34","author":"A Wright Willis","year":"2010","unstructured":"Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34(3):143\u201351.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"5385_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamaneurol.2018.2820","volume":"76","author":"S Mantri","year":"2019","unstructured":"Mantri S, Fullard M, Gray SL, Weintraub D, Hubbard RA, Hennessy S, et al. Patterns of dementia treatment and frank prescribing errors in older adults with Parkinson disease. JAMA Neurol. 2019;76(1):41\u20139.","journal-title":"JAMA Neurol"},{"issue":"10","key":"5385_CR7","volume":"10","author":"K Tanveer","year":"2018","unstructured":"Tanveer K, Attique I, Sadiq W, Ahmad A. Non-motor symptoms in patients with Parkinson\u2019s disease: a cross-sectional survey. Cureus. 2018;10(10): e3412.","journal-title":"Cureus"},{"issue":"21","key":"5385_CR8","doi-asserted-by":"crossref","first-page":"e2170","DOI":"10.1212\/WNL.0000000000207247","volume":"100","author":"DG Di Luca","year":"2023","unstructured":"Di Luca DG, Luo S, Liu H, Cohn M, Davis TL, Ramirez-Zamora A, et al. Racial and ethnic differences in health-related quality of life for individuals with Parkinson disease across centers of excellence. Neurology. 2023;100(21):e2170\u201381.","journal-title":"Neurology"},{"key":"5385_CR9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3823\/2516","volume":"10","author":"R Wijeyekoon","year":"2017","unstructured":"Wijeyekoon R, Suriyakumara V, Gamage R, Fernando T, Jayasuriya A, Amarasinghe D, et al. Associations between lifestyle factors and Parkinson\u2019s disease in an urban Sri Lankan clinic study. Int Arch Med. 2017;10:246.","journal-title":"Int Arch Med"},{"issue":"11","key":"5385_CR10","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1586\/14737175.2015.1088783","volume":"15","author":"R Bhidayasiri","year":"2015","unstructured":"Bhidayasiri R, Hattori N, Jeon B, Chen RS, Lee MK, Bajwa JA, et al. Asian perspectives on the recognition and management of levodopa \u2018wearing-off\u2019 in Parkinson\u2019s disease. Expert Rev Neurother. 2015;15(11):1285\u201397.","journal-title":"Expert Rev Neurother"},{"key":"5385_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/08971900221151194","volume":"37","author":"C Livingston","year":"2023","unstructured":"Livingston C, Monroe-Duprey L. A review of levodopa formulations for the treatment of Parkinson\u2019s disease available in the United States. J Pharm Pract. 2023;37:485\u201394.","journal-title":"J Pharm Pract"},{"issue":"2","key":"5385_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/mds.29685","volume":"39","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Hauser RA, Dhall R, Thakkar S, Cloud L, Zeitlin L, et al. Safety and efficacy of IPX203 in Parkinson\u2019s disease: the RISE-PD open-label extension study. Mov Disord. 2024;39(2):428\u201332.","journal-title":"Mov Disord"},{"issue":"10","key":"5385_CR13","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","volume":"80","author":"RA Hauser","year":"2023","unstructured":"Hauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA, et al. IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease: the RISE-PD randomized clinical trial. JAMA Neurol. 2023;80(10):1062\u20139.","journal-title":"JAMA Neurol"},{"key":"5385_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2021.10.001","volume":"92","author":"L Cook","year":"2021","unstructured":"Cook L, Schulze J, Verbrugge J, Beck JC, Marder KS, Saunders-Pullman R, et al. The commercial genetic testing landscape for Parkinson\u2019s disease. Parkinsonism Relat Disord. 2021;92:107\u201311.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"5385_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.2174\/1389202914666131210210241","volume":"14","author":"J Dorszewska","year":"2013","unstructured":"Dorszewska J, Prendecki M, Oczkowska A, Rozycka A, Lianeri M, Kozubski W. Polymorphism of the COMT, MAO, DAT, NET and 5-HTT genes, and biogenic amines in Parkinson\u2019s disease. Curr Genomics. 2013;14(8):518\u201333.","journal-title":"Curr Genomics"},{"issue":"12","key":"5385_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","volume":"20","author":"F Stocchi","year":"2024","unstructured":"Stocchi F, Bravi D, Emmi A, Antonini A. Parkinson disease therapy: current strategies and future research priorities. Nat Rev Neurol. 2024;20(12):695\u2013707.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"5385_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/ijms18030551","volume":"18","author":"R Cacabelos","year":"2017","unstructured":"Cacabelos R. Parkinson\u2019s disease: from pathogenesis to pharmacogenomics. Int J Mol Sci. 2017;18(3):551.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5385_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41588-023-01584-8","volume":"56","author":"JJ Kim","year":"2024","unstructured":"Kim JJ, Vitale D, Otani DV, Lian MM, Heilbron K, Me Research T, et al. Multi-ancestry genome-wide association meta-analysis of Parkinson\u2019s disease. Nat Genet. 2024;56(1):27\u201336.","journal-title":"Nat Genet"},{"key":"5385_CR19","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.12294","volume":"9","author":"N Bharti","year":"2021","unstructured":"Bharti N, Banerjee R, Achalere A, Kasibhatla SM, Joshi R. Genetic diversity of \u2018Very Important Pharmacogenes\u2019 in two South-Asian populations. PeerJ. 2021;9: e12294.","journal-title":"PeerJ"},{"issue":"8","key":"5385_CR20","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/mds.29442","volume":"38","author":"R Saunders-Pullman","year":"2023","unstructured":"Saunders-Pullman R, Raymond D, Ortega RA, Shalash A, Gatto E, Salari M, et al. International genetic testing and counseling practices for Parkinson\u2019s disease. Mov Disord. 2023;38(8):1527\u201335.","journal-title":"Mov Disord"},{"issue":"2","key":"5385_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200138","volume":"13","author":"WW Aamodt","year":"2023","unstructured":"Aamodt WW, Willis AW, Dahodwala N. Racial and ethnic disparities in Parkinson disease: a call to action. Neurol Clin Pract. 2023;13(2): e200138.","journal-title":"Neurol Clin Pract"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05385-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05385-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05385-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T09:04:02Z","timestamp":1751879042000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05385-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5385"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05385-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"9 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to participate has been obtained from the patient. Formal IRB review is not required for a single de-identified case.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"321"}}